Biotechnology News and Research

RSS

Teva exercises option to invest additional $11.9M in Andromeda Biotech

Andromeda Biotech Ltd. announces that Teva Pharmaceutical Industries Ltd. decided to exercise its option to invest in Andromeda Biotech Ltd. at a company per-money valuation of 170 million US dollars.

17 Jun 2010

Kun Run Biotechnology obtains China SFDA manufacturing approval for Entecavir

Kun Run Biotechnology, Inc., a leading bio-pharmaceutical company in China focusing on manufacturing and sales of peptide-based and small molecule drugs, today announced that they have obtained the manufacturing approval for Entecavir from the China State Food and Drug Administration (SFDA).

17 Jun 2010

Scientific American publishes article on "rebirth" of DNA vaccines

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Scientific American magazine has published in its July issue an article entitled "DNA Drugs Come of Age." The article was co-authored by Dr. David Weiner, Chairman, Scientific Advisory Board, Inovio Pharmaceuticals, and Professor, Department of Pathology & Laboratory Medicine, at the University of Pennsylvania and Dr. Matthew Morrow, a post-doctorate research fellow at University of Pennsylvania.

17 Jun 2010

ACT awarded patent for production processes of RPE cells from hESCs

Advanced Cell Technology, Inc., a leader in the field of regenerative medicine, announced today that it has been issued U.S. Patent Number 7736896, which is broadly directed to processes developed by ACT scientists for the production of retinal pigment epithelial (RPE) cells from human embryonic stem cells (hESCs).

17 Jun 2010

VBL presents positive preclinical data on VB-201 for rheumatoid arthritis at EULAR

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 possesses anti-inflammatory properties and effectively reduced the symptoms of arthritis in experimental models.

17 Jun 2010

Selection of candidate in oncology programme triggers EUR 2.5 million milestone payment to Evotec

Evotec AG today announced that it has achieved a milestone as part of its research alliance with Boehringer Ingelheim and will receive a payment of EUR 2.5 million. The milestone was achieved for the selection of a candidate compound for pre-development studies in an oncology programme.

17 Jun 2010

Research studies may lead to future development of cell transplant therapy for ALS

The University of California, San Diego, The Salk Institute for Biological Studies and Life Technologies Corporation today announced the initiation of studies which may lead to the future development of cell transplant therapy for amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. Currently, there is only one FDA-approved pharmaceutical addressing this lethal disease, which affects approximately 30,000 people in the United States.

17 Jun 2010

Stony Brook team creates live attenuated influenza virus vaccine by computer-aided rational design

A team of molecular biologists and computer scientists at Stony Brook University have used a novel method to weaken (attenuate) influenza virus by way of designing hundreds of mutations to its genetic code to create an effective vaccine. Reported online and in the July issue of Nature Biotechnology, the method may be a major step in developing more effective and safe vaccines against influenza, which claims 250,000 to 500,000 lives annually worldwide, partly because existing vaccines are not fully effective.

17 Jun 2010

Positive results from Cytomedix's AutoloGel System study for treatment of advanced, chronic wounds published

Cytomedix, Inc., a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that positive results from a prospective study evaluating the AutoloGel™ System to treat advanced, chronic wounds was published in the June 2010 issue of Ostomy Wound Management in a peer reviewed article entitled, "Chronic Wounds Treated With a Physiologically Relevant Concentration of Platelet-rich Plasma (PRP) Gel: A Prospective Case Series."

17 Jun 2010

QR Pharma, Massachusetts General Hospital announce Parkinson's disease research collaboration

QR Pharma, Inc. (QR) and Massachusetts General Hospital announced today a new collaborative research agreement to work on a treatment for Parkinson's disease (PD).

17 Jun 2010

FDA approves clinical testing of SanBio's SB623 for stroke recovery

SanBio Inc. announced today that the United States Food and Drug Administration (FDA) has approved the clinical testing of their SB623 regenerative medicine product in patients suffering from disability caused by cerebral stroke. SB623 is derived from bone marrow stromal cells (MSCs) isolated from healthy adult donors.

17 Jun 2010

Discovery Labs proposes common stock public offering

Discovery Laboratories, Inc. today announced that it intends to offer, subject to market and other conditions, shares of its common stock and common stock purchase warrants.

17 Jun 2010

Oncodesign announces technology license agreement with Janssen Pharmaceutica

Oncodesign Biotechnology(R) announced today that it has signed a licensing agreement with Janssen Pharmaceutica NV (hereinafter Janssen) related to Janssen’s macrocyclic chemistry technology. Oncodesign will have exclusive access to this technology for six years.

16 Jun 2010

PRA International Clinical Research Organization opens Phase I facility in Budapest

PRA International, a leading Clinical Research Organization, announces the opening of a Phase I facility in Budapest, Hungary that will provide "unit-on-demand" service and further enhance PRA's capabilities for conducting early-development trials in patients.

16 Jun 2010

GTC Biotherapeutics closes new $7 million secured convertible debt financing

GTC Biotherapeutics, Inc. announced the closing of a new $7 million secured convertible debt financing by its strategic partner, LFB Biotechnologies SAS, in connection with a restructuring of GTC's operations which will result in a downsizing of approximately 30 full-time positions at its headquarters and an additional 20 positions at its farm facility.

16 Jun 2010

Life Technologies forms GIBCO Cell Therapy Systems

Life Technologies Corporation today announced the formation of GIBCO® Cell Therapy Systems (CTS™), which will offer the life science industry's widest array of products to support cell therapy applications, including regenerative medicine. Specifically designed to help cell therapy practitioners accelerate the transition from research to clinical applications, the product portfolio will include a broad and deep offering of Invitrogen devices and reagents.

16 Jun 2010

Hamilton Thorne announces launch of Staccato multi-pulse laser system at 8th ISSCR Annual Meeting

Hamilton Thorne Ltd., a leading provider of advanced laser systems and instruments for the stem cell research and fertility clinic markets, today announced the launch of the Staccato(TM) multi-pulse laser system at the 8th Annual Meeting of the International Society of Stem Cell Research (ISSCR), June 16-19, 2010, in San Francisco, CA. Staccato(TM) will add to the functionality of the XYClone(R) laser system, providing the ability of near-continuous application of the laser to the sample through rapid pulsing of the beam.

16 Jun 2010

Independent SMB recommends continuance of Allovectin-7 Phase 3 trial for metastatic melanoma

Vical Incorporated today announced that an independent Safety Monitoring Board (SMB) for the company's Phase 3 trial of Allovectin-7® in patients with metastatic melanoma has completed the trial's fourth scheduled safety analysis and recommended that the trial continue per the protocol.

16 Jun 2010

Minapharm Pharmaceuticals acquires 95% of the share capital of ProBioGen

ProBioGen AG announced today that Minapharm Pharmaceuticals, Cairo, has completed the acquisition of 95 % of the share capital of ProBioGen, an internationally renowned German cell line development and contract manufacturing specialist. The total purchase price of EUR 30.4 million includes earn-out payments which are conditional upon the achievement of defined milestones.

16 Jun 2010

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

NexMed, Inc., a specialty CRO with a pipeline of products based on the NexACT® technology, today announced results from a pre-clinical study showing that calcipotriene 0.005% and betamethasone dipropionate 0.064%, when formulated with NexACT®, results in a topical treatment which shows bioequivalecy in efficacy to Talconex®, one of the leading topical treatments marketed for patients with mild to moderate psoriasis.

16 Jun 2010

Biotechnology News and Research

Teva exercises option to invest additional $11.9M in Andromeda Biotech

Kun Run Biotechnology obtains China SFDA manufacturing approval for Entecavir

Scientific American publishes article on "rebirth" of DNA vaccines

ACT awarded patent for production processes of RPE cells from hESCs

VBL presents positive preclinical data on VB-201 for rheumatoid arthritis at EULAR

Selection of candidate in oncology programme triggers EUR 2.5 million milestone payment to Evotec

Research studies may lead to future development of cell transplant therapy for ALS

Stony Brook team creates live attenuated influenza virus vaccine by computer-aided rational design

Positive results from Cytomedix's AutoloGel System study for treatment of advanced, chronic wounds published

QR Pharma, Massachusetts General Hospital announce Parkinson's disease research collaboration

FDA approves clinical testing of SanBio's SB623 for stroke recovery

Discovery Labs proposes common stock public offering

Oncodesign announces technology license agreement with Janssen Pharmaceutica

PRA International Clinical Research Organization opens Phase I facility in Budapest

GTC Biotherapeutics closes new $7 million secured convertible debt financing

Life Technologies forms GIBCO Cell Therapy Systems

Hamilton Thorne announces launch of Staccato multi-pulse laser system at 8th ISSCR Annual Meeting

Independent SMB recommends continuance of Allovectin-7 Phase 3 trial for metastatic melanoma

Minapharm Pharmaceuticals acquires 95% of the share capital of ProBioGen

NexMed's NexACT-based topical psoriasis treatment bioequivalent to Talconex

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News